Evidence map›Paper›PMID 34707710›Full record

ReviewExperimental and therapeutic medicine2021

Management of psoriasis in children (Review).

Daciana Elena Branisteanu, Simona Georgescu, Ionela Lacramioara Serban, Alin Constantin Pinzariu, Daniel Boda, Minela Aida Maranduca, Mihai Glod, Catalina Ioana Branisteanu, Roxana Bilibau, Andreea Dimitriu and 2 more

Open access · diamondAbstract readReview
In one paragraph

Review in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Daciana Elena BranisteanuDepartment of Dermatology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.
Simona GeorgescuDepartment of Dermatology, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Ionela Lacramioara SerbanDepartment of Physiology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.
Alin Constantin PinzariuDepartment of Physiology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.
Daniel BodaDepartment of Dermatology, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Minela Aida MaranducaDepartment of Physiology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.
Mihai GlodDepartment of Surgery, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.
Catalina Ioana Branisteanu'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.
Roxana BilibauDepartment of Dermatology, 'Railway Clinical Hospital', 700506 Iasi, Romania.
Andreea DimitriuDepartment of Dermatology, 'Arcadia Hospitals and Medical Centers', 700620 Iasi, Romania.
Alin Codrut NicolescuDepartment of Dermatology, Roma Medical Center for Diagnosis and Treatment, 011773 Bucharest, Romania.
Daniel Constantin BranisteanuDepartment of Ophthalmology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.
Grigore T. Popa University of Medicine and Pharmacy · ROCarol Davila University of Medicine and Pharmacy · ROClinical Emergency Hospital Bucharest · ROInstitute for Diagnosis and Animal Health · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is a common long-lasting, inflammatory disease that mainly affects the skin. The incidence of this condition has increased significantly over time and at this point, it affects approximately 1% of children. Psoriasis can appear at any age, including childhood and adolescence, with a higher frequency in girls, an earlier onset being associated with severe psoriasis. The pathology is the result of the interaction between genetics and trigger factors such as infections, stress, diet, obesity, and chemical irritants. Paradoxically, tumor necrosis factor (TNF)-α inhibitors (infliximab, adalimumab) may induce psoriasis in children. Psoriasis is a long-term condition with periods of exacerbation; thus, the quality of life can be affected and patients should receive psychosocial support. Although most children have mild disease and topical treatment is efficient, some cases are challenging to treat. The aim of this review was to provide an overview of the current knowledge concerning the epidemiology, etiology, pathogenesis, clinical features, comorbidities, and treatment of psoriasis in children and also to emphasize the need for a multidisciplinary approach to this complex pathology.

Indexed as

biologic therapiesmanagementnapkin psoriasispathogenesispsoriasis in childrentreatment

Identifiers

PMID34707710
PMCPMC8543441
OpenAlexW3206469927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.